Expert Interview
Exploring the Potential of Selinexor and Ruxolitinib in Myelofibrosis from Karyopharm Therapeutics' Phase 3 SENTRY Trial
Ticker(s): KPTI, INCY, BMY, GSK, CTICInstitution: McGill (Jewish General Hospital)
- Assistant Professor of Oncology at McGill.
- Manages ~30 MF patients/month.
- Established the first myeloproliferative neoplasms clinic in Canada; has authored several publications in the area of MPN clinical research and has been an investigator on several clinical trials assessing novel agents in the treatment of MPN.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
